Bartlett & CO. Wealth Management LLC Grows Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Bartlett & CO. Wealth Management LLC raised its stake in Thermo Fisher Scientific by 1.1% in Q4 to 194,369 shares, a holding worth about $112.7 million that made the stock its 18th-largest position.
• Thermo Fisher beat Q4 expectations with EPS of $6.57 (vs. $6.45 est.) and revenue of $12.22 billion, up 7.2% year-over-year, and analysts project roughly 23.28 earnings per share for the fiscal year.
• The company raised its quarterly dividend to $0.47 (annualized $1.88) for a yield of about 0.4%; the ex-dividend date is March 13 and the payment date is April 15.

Bartlett & CO. Wealth Management LLC raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.1% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 194,369 shares of the medical research company's stock after purchasing an additional 2,109 shares during the period. Thermo Fisher Scientific comprises approximately 1.5% of Bartlett & CO. Wealth Management LLC's portfolio, making the stock its 18th biggest holding. Bartlett & CO. Wealth Management LLC owned 0.05% of Thermo Fisher Scientific worth $112,701,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. JPL Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the third quarter valued at $28,000. Highline Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 126.9% in the 3rd quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company's stock worth $29,000 after purchasing an additional 33 shares during the period. Beacon Financial Strategies CORP purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Olistico Wealth LLC purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Finally, Capital A Wealth Management LLC increased its holdings in Thermo Fisher Scientific by 825.0% during the 2nd quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company's stock worth $30,000 after purchasing an additional 66 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Down 0.8%

NYSE:TMO opened at $496.34 on Friday. The firm has a market capitalization of $184.45 billion, a price-to-earnings ratio of 27.98, a PEG ratio of 2.68 and a beta of 0.97. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99. The company has a current ratio of 1.89, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67. The business's fifty day moving average price is $505.33 and its 200 day moving average price is $548.30.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, beating the consensus estimate of $6.45 by $0.12. The firm had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.Thermo Fisher Scientific's quarterly revenue was up 7.2% on a year-over-year basis. During the same period in the previous year, the firm earned $6.10 earnings per share. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.43. The ex-dividend date is Friday, March 13th. Thermo Fisher Scientific's dividend payout ratio is presently 10.60%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $541.20, for a total value of $216,480.00. Following the transaction, the executive vice president owned 20,752 shares in the company, valued at $11,230,982.40. The trade was a 1.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 5,000 shares of the business's stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. This trade represents a 3.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.33% of the company's stock.

Analyst Ratings Changes

TMO has been the subject of several research reports. DZ Bank assumed coverage on Thermo Fisher Scientific in a research report on Friday, March 27th. They issued a "buy" rating and a $610.00 target price for the company. Stifel Nicolaus boosted their price target on Thermo Fisher Scientific from $583.00 to $700.00 and gave the stock a "buy" rating in a research report on Friday, January 9th. Barclays boosted their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an "overweight" rating in a research report on Friday, January 30th. Weiss Ratings reiterated a "hold (c)" rating on shares of Thermo Fisher Scientific in a research report on Wednesday. Finally, Evercore reiterated an "outperform" rating and set a $650.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and an average price target of $632.50.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.